Loading clinical trials...

Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion | Clinical Trials | Clareo Health

COMPLETEDPhase 4NCT00160199

Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion

To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea

Lead sponsor: Solvay Pharmaceuticals•42 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment240

Start dateNov 2004

Last updatedJul 7, 2010

Condition

Secondary Amenorrhea

Locations shown

Site 29

Mobile, Alabama

Site 41

Montgomery, Alabama

Site 26

Tucson, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 7, 2010Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions